Unlocking The Potential of IGHVIII-11-1 for Therapeutic Interventions

Target Name: IGHVIII-11-1

NCBI ID: G28352

IGHVIII-11-1

Other Name(s): IGHVIII111 | Immunoglobulin heavy variable (III)-11-1 (pseudogene) | immunoglobulin heavy variable (III)-11-1 (pseudogene) | 3-11.1P

Unlocking The Potential of IGHVIII-11-1 for Therapeutic Interventions

IGHVIII-11-1 (IGHVIII111) is a glycoprotein that is expressed in various tissues of the body, including the liver, spleen, and peripheral blood cells. It is a type of transmembrane protein that is characterized by the presence of an N-terminal glycosylated region and a C-terminal region that is involved in interactions with other proteins.

One of the unique features of IGHVIII-11-1 is its structure. It has a five-pass transmembrane structure, which means that it spans the entire cell membrane and is involved in various cellular processes. The five-pass structure allows IGHVIII- 11-1 to interact with a wide range of proteins, which has important implications for its function in the body.

IGHVIII111 has been shown to play a number of important roles in the immune system. For example, it is involved in the antigen presentation process, which is the process by which antigen is processed and presented to T-cells so that they can be activated in the fight against infection. In addition, IGHVIII111 is also involved in the regulation of the immune response, as well as in the regulation of inflammation.

Another important function of IGHVIII-11-1 is its potential as a drug target. Its five-pass structure and the involvement in various cellular processes make it an attractive target for small molecules, antibodies, and other therapeutic agents. Additionally, its role in the immune system makes it an attractive target for vaccines and other immunomodulatory drugs.

IGHVIII111 has also been shown to be involved in the regulation of cellular processes that are important for the development and progression of various diseases, including cancer. For example, studies have shown that IGHVIII111 is involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed. This is important because increased angiogenesis has been implicated in the development of many types of cancer.

In addition, IGHVIII111 has also been shown to be involved in the regulation of cellular processes that are important for the regulation of inflammation. This is important because chronic inflammation is a major risk factor for the development of many types of diseases, including cardiovascular disease and autoimmune disorders.

Overall, IGHVIII-11-1 (IGHVIII111) is a protein that has important implications for a wide range of biological processes in the body. Its five-pass transmembrane structure and its involvement in various cellular processes make it an attractive target for small molecules , antibodies, and other therapeutic agents. Additionally, its role in the immune system and its potential as a drug target make it an important molecule to study further.

Protein Name: Immunoglobulin Heavy Variable (III)-11-1 (pseudogene)

The "IGHVIII-11-1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGHVIII-11-1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets